Table 6: Results of probabilistic sensitivity analysis (Monte Carlo Simulation).
| Comparators | Mean Cost per patient (€ [USD]) | Standard Deviation (± SD) | Incremental Cost (€ [USD])* |
|---|---|---|---|
| Apixaban | 1,608.26 [1816.53] | 107.33 [121.23] | 707.79 [799.45] |
| VKA | 900.47 [1017.08] | 46.08 [52.05] | 0 [0] |
| Dabigatran | 1,477.53 [1668.87] | 97.42 [110.04] | 719.95 [813.18] |
| VKA | 757.58 [855.69] | 41.88 [47.3] | 0 [0] |
| Edoxaban | 1,376.91 [1555.22] | 89.46 [101.05] | 619.2 [699.39] |
| VKA | 757.71 [855.83] | 41.06 [46.38] | 0 [0] |
| Rivaroxaban | 1,511.97 [1707.77] | 99.44 [112.32] | 785.24 [886.93] |
| VKA | 726.73 [820.84] | 78.52 [88.69] | 0 [0] |
*Incremental cost denotes the increase in total costs resulting from administering the respective NOAC versus anticoagulation with VKA (phenprocoumon) patients utilizing PST.